drugset / Trial / NCT00246064

The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol

NCT00246064

Phase 4 Completed 210 enrolled Centocor Ortho Biotech Services, L.L.C.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study was to evaluate the ability of a maintenance dosage regimen of infliximab to achieve and sustain at least 40% improvement from baseline in the total joint count in patients with active Rheumatoid Arthritis (RA) during methotrexate tapering.

Timeline

Start
2001-12
Primary completion
Completion
2003-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Infliximab Monoclonal antibody 3 mg/kg
Subject Infliximab Monoclonal antibody 10 mg/kg

Indications